MindWalk Holdings Corp
MindWalk Holdings Corp is a Canadian-based company operating in the pharmaceuticals and medical research industry, primarily generating revenue through the development and commercialization of digital therapeutics and related healthcare technologies.
Business. MindWalk Holdings Corp (HYFT.O) is a pharmaceutical company engaged in pharmaceuticals and medical research. The firm is headquartered in the United States and is primarily listed on the NASDAQ exchange. Specific details regarding operating segments and geographic revenue mix are not available.
Analyst recommendations
3 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
MindWalk Holdings Corp (HYFT.O) is a pharmaceutical company engaged in pharmaceuticals and medical research. The firm is headquartered in the United States and is primarily listed on the NASDAQ exchange. Specific details regarding operating segments and geographic revenue mix are not available.
MindWalk Holdings Corp has a market capitalization of CAD 56.05 million and a price-to-book ratio of 2.37, indicating a premium valuation relative to its book value. The company's liquidity position is characterized as medium, with a current ratio of 2.08, suggesting it can cover its short-term liabilities with its current assets. However, the company's operating cash flow is negative at CAD -6.41 million, and its free cash flow is also negative at CAD -26.17 million, indicating a lack of cash generation from operations.
Profitability metrics show that the company is not currently generating positive returns. The return on equity is -127.97%, and the return on assets is -68.03%, both significantly below industry norms for a profitable pharmaceutical company. The company's operating income is negative at CAD -33.56 million, and its net income is also negative at CAD -30.23 million, indicating a substantial loss-making position.
The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no significant geographic diversification reported. This lack of diversification may expose the company to higher operational and market risks if its primary product or service faces regulatory or market challenges.
The company's growth trajectory is uncertain, with no clear indication of revenue growth in the current fiscal year. The operating income and net income have both declined, and the company has not provided specific guidance for the next fiscal year. The negative cash flows and lack of profitability raise concerns about the company's ability to sustain operations without additional financing.
The risk assessment indicates a medium liquidity risk, with the company's net cash position being negative after accounting for total debt. The dilution risk is assessed as low, with no immediate pressure for share issuance or dilution. The company's debt-to-equity ratio of 0.57 suggests a moderate level of leverage, but the negative operating cash flow may limit its ability to service debt obligations.
Recent events and filings do not indicate any significant changes in the company's strategic direction or financial position. The company has not disclosed any major product launches, partnerships, or regulatory approvals that could drive future revenue growth. Analysts have provided a mean price target of CAD 4.00, with a median price target of CAD 4.00, suggesting a potential upside from the current market price of CAD 1.20.
- The company is currently unprofitable, with a negative return on equity and return on assets.
- The company's liquidity position is medium, with a current ratio of 2.08, but it has negative operating and free cash flows.
- The company's revenue is concentrated in a single business segment, with no significant geographic diversification.
- Analysts have provided a mean price target of CAD 4.00, indicating a potential upside from the current market price.
- The company's debt-to-equity ratio is 0.57, suggesting a moderate level of leverage.
- "margin_outlook_rationale": "The company's operating and net margins are negative, indicating a lack of profitability and no clear improvement in the near term.",
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -0,31 |
| Revenue | —no estimate | —no estimate | 15,9M CAD |
| Operating income | —no estimate | —no estimate | -13,9M CAD |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Ev To Revenueenterprise_value / revenue
- MindWalk Holdings Corp Market data — financials · 2026-05-28
- MindWalk Holdings Corp Market data — analyst estimates · 2026-05-28
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
Leadership
- Jennifer Lynne BathPresident, Chief Executive Officer, Director